Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Corneal News

11/14/2024
AAOCornealMeetingNewsletter
Cornea and Eye Banking Forum Looks at Ways to Expand the Donor Pool
Cornea and Eye Banking Forum Looks at Ways  to Expand the Donor Pool

Expanding the donor pool was once again top of mind at the 2024 Cornea and Eye Banking Forum, held Oct. 18 in conjunction with the AAO meeting in Chicago, Illinois. The forum, supported by the Eye ...

11/14/2024
AllergyCataractClinical TrialCornealGlaucomaNewsletterPresbyopiaRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Clinical Trial Updates for Ophthalmic Candidates, November 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

11/8/2024
BreakingCataractCornealDry EyeGlaucomaLaserPharmaPresbyopiaRefractiveRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

10/25/2024
BreakingCornealDealsDry EyeFundingStudy
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure

Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...

10/18/2024
BreakingCataractCornealSurgical
Cure Blindness Project Expands Sight-Saving Care to Six New Countries
Cure Blindness Project Expands Sight-Saving Care to Six New Countries

Cure Blindness Project is expanding to six new countries—Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia, the charity reported Oct. 10. Paraguay marksthe charity’...

10/15/2024
CornealDiagnosticGlaucomaLaserNewsletterRegulation
Select US FDA Approvals and Clearances in September 2024
Select US FDA Approvals and Clearances in September 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in September 2024, according to the agency’s database. Zeiss gained clearance for its combination Y...

10/15/2024
CornealNewsletter
Aurion Biotech Launches Vyznova Corneal Cell Therapy in Japan
Aurion Biotech Launches Vyznova Corneal Cell Therapy in Japan

Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...

10/15/2024
CornealESCRSEuropeMeetingNewsletter
Cornea Surgeons Examine New Crosslinking Options and Old Debates
Cornea Surgeons Examine New Crosslinking Options and Old Debates

Farhad Hafezi, MD, PhD, FARVO (Switzerland), discussed at the 2024 ESCRS congress the goals of the second global consensus on keratoconus, being drafted in 2024. This consensus encompasses feedback...

10/15/2024
Clinical TrialCornealDry EyeGene TherapyGlaucomaIOLNewsletterOcular CancerRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/4/2024
BreakingCornealEurope
SIFI Launches Akantior Drops for Acanthamoeba Keratitis in Germany
SIFI Launches Akantior Drops for Acanthamoeba Keratitis in Germany

Italy’s SIFI announced Sept. 30 the launch in Germany of its Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in patients 12 a...

10/4/2024
BreakingCornealRegulation
Aurion Launches Vyznova Corneal Cell Therapy in Japan
Aurion Launches Vyznova Corneal Cell Therapy in Japan

Aurion Biotech announced Sept. 24 that it had launched Vyznova (neltependocel), a cell therapy for bullous keratopathy of the cornea, in Japan. Japanese regulators approved Vyznova in March 2023. T...

8/30/2024
BreakingCornealEuropePharmaRegulation
European Commission Approves SIFI’s Akantior Drops for Acanthamoeba Keratitis
European Commission Approves SIFI’s Akantior Drops for Acanthamoeba Keratitis

Italy’s SIFI announced Aug. 26 that the European Commission had approved Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in p...

8/21/2024
CornealDry EyeEmergingNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2024
Emerging Companies Pursuing Ophthalmic Indications, August 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

8/21/2024
CataractCornealNewsletterSurgical
Renowned Charity HCP Cureblindness Rebrands as Cure Blindness Project
Renowned Charity HCP Cureblindness Rebrands as Cure Blindness Project

HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...

8/21/2024
BiosimilarsCornealDealsDry EyeEuropeGene TherapyGenericsIndustryLow VisionNewsletterOcular CancerPharmaPresbyopiaRegulationRetina
August 2024 Ophthalmic News Briefs
August 2024 Ophthalmic News Briefs

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...

8/16/2024
BreakingCornealDealsPharma
Santen Licenses Cloudbreak Topical Pterygium Candidate for Japan, Korea, and Southeast Asia
Santen Licenses Cloudbreak Topical Pterygium Candidate for Japan, Korea, and Southeast Asia

Japan’s Santen announced Aug. 6 that it had signed an agreement to license CBT-001, a topical pterygiumtreatment candidate from Cloudbreak Pharma. The deal covers the territories of Japan, South Ko...

8/9/2024
BreakingCornealRetina
Mallinckrodt Announces Availability of Acthar Gel SelfJect Injector in the US
Mallinckrodt Announces Availability of Acthar Gel SelfJect Injector in the US

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application (sNDA...

8/9/2024
BreakingCataractCornealSurgical
HCP Cureblindness Rebrands as Cure Blindness Project
HCP Cureblindness Rebrands as Cure Blindness Project

HCP Cureblindness has rebranded as the Cure Blindness Project, the group announced July 29. The move is designed to better reflect the eye charity’s expanded geographical footprint and commitment t...

8/2/2024
BreakingCornealDiagnosticDry EyeGlaucomaIOLLaserRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...

7/26/2024
BreakingCornealDealsDiagnosticDry EyeSurgical
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/26/2024
BreakingCornealDealsDry EyeIndustry
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser

Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...

7/26/2024
BreakingCornealEuropeRegulation
Advisory Panel Recommends Orphan Drug Status for SIFI’s Polihexanide in Fungal Keratitis
Advisory Panel Recommends Orphan Drug Status for SIFI’s Polihexanide in Fungal Keratitis

Italy’s SIFI announced July 22 that a European advisory panel had recommended orphan drug designation for its polihexanide eye drop for fungal keratitis. The Committee for Orphan Medicinal Products...

7/23/2024
BiosimilarsCornealFundingGene TherapyMyopiaNewsletterPresbyopiaRetina
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B

Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...

7/23/2024
CornealNewsletter
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101

Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...

7/23/2024
BiosimilarsClinical TrialCornealDealsDry EyeEuropeGene TherapyGlaucomaIndiaIndustryMyopiaNewsletterRegulationRetina
July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/19/2024
BreakingCorneal
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101
Claes H. Dohlman, MD, PhD, Corneal Research Pioneer and Inventor of the Boston KPro, Dies at 101

Claes H. Dohlman, MD, PhD, considered by many to be the father of modern corneal science, died July 14, Massachusetts Eye and Ear announced in a press release. He was 101. Dohlman, who was born in ...

7/19/2024
BreakingClinical TrialCornealDry Eye
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain

London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...

7/5/2024
BreakingCornealDealsFundingRefractive
J&J Leads Series A Round for Crosslinking Tech Developer TecLens
J&J Leads Series A Round for Crosslinking Tech Developer TecLens

Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...

7/5/2024
BreakingCornealRegulation
US FDA Grants Breakthrough, Regenerative Medicine Status to Aurion’s Corneal Cell Therapy Candidate
US FDA Grants Breakthrough, Regenerative Medicine Status to Aurion’s Corneal Cell Therapy Candidate

Aurion Biotech announced June 19 that the US FDA had granted both breakthrough therapy and regenerative medicine advanced therapy status for AURN001, the company’s allogeneic cell therapy candidate...

6/24/2024
CornealMeetingNewsletter
Eye Banking Meeting Celebrates Successful Transplants, Looks at Needs Going Forward
Eye Banking Meeting Celebrates Successful Transplants, Looks at Needs Going Forward

Attendees at the 2024 Eye Banking Association of America (EBAA) meeting celebrated many achievements and milestones across the eye banking profession and transplant community in general, as 2023 ma...

6/24/2024
CornealEuropeNewsletterRegulation
SIFI’s Acanthamoeba Keratitis Eye Drop Candidate Gains Positive CHMP Opinion
SIFI’s Acanthamoeba Keratitis Eye Drop Candidate Gains Positive CHMP Opinion

Italy’s SIFI announced May 31 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of Akantior (polihexanide 0.08%) for the treatment...

6/24/2024
CornealDealsDiagnosticNewsletter
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues
Eversight Partners with LighTopTech  to Improve Imaging of Eye Tissues

Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...

6/24/2024
CornealDry EyeNewsletter
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders

BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...

6/21/2024
BreakingCornealDealsDiagnostic
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues
Eversight Partners with LighTopTech to Improve Imaging of Eye Tissues

Global nonprofit eye bank Eversight announced June 5 a four-year partnership with LighTopTech to improve imaging for eye tissues in clinical and research settings. Eversight will integrate LighTopT...

6/14/2024
BreakingCornealDry Eye
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders

BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...

6/7/2024
BreakingCornealEuropeRegulation
Acanthamoeba Keratitis Eye Drop Candidate from SIFI Gains Positive CHMP Opinion
Acanthamoeba Keratitis Eye Drop Candidate from SIFI Gains Positive CHMP Opinion

Italy’s SIFI announced May 31 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of Akantior (polihexanide 0.08%) for the treatment...

5/22/2024
CornealDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterOcular CancerRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

5/22/2024
CornealGlaucomaMeetingNewsletterOcular CancerRetinaStudy
2024 ARVO Awards Highlight New Focus on Inflammation
2024 ARVO Awards Highlight New Focus on Inflammation

The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...

5/22/2024
CataractClinical TrialCornealGene TherapyGlaucomaNewsletterPharmaRefractiveRetina
Clinical Trial Updates for Ophthalmic Candidates, May 2024
Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

5/22/2024
CataractChinaCornealDiagnosticDry EyeGlaucomaIndiaMicroscopesNewsletterPharmaRegulationRetina
May 2024 Ophthalmic News Briefs
May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

5/10/2024
BreakingCornealRefractive
Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the US
Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the US

Bausch + Lomb announced May 7 that it had launched the Zenlens Echo, a non-prosthetic, custom scleral contact lens, in the US. The company said the Echo is designed to fit a wide variety of corneal...

4/24/2024
AICataractCornealDiagnosticFundingGlaucomaIndiaLaserNewsletterPharmaRetina
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

4/24/2024
ASCRSCornealNewsletter
Rise of DMEK Highlights Need for Corneal Endothelial Therapies
Rise of DMEK Highlights Need for Corneal Endothelial Therapies

Descemet’s membrane endothelial keratoplasty (DMEK) has become the most common keratoplasty procedure performed domestically, according to a statistical report by the Eye Bank Association of Americ...

4/24/2024
CornealEmergingIndiaNewsletter
Emerging Companies Pursuing Ophthalmic Indications, April 2024
Emerging Companies Pursuing Ophthalmic Indications, April 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

4/24/2024
Clinical TrialCornealGene TherapyGlaucomaLow VisionNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates , April 2024
Clinical Trial Updates for Ophthalmic Candidates , April 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

4/24/2024
Clinical TrialCornealData SecurityDealsDiagnosticDry EyeEnvironmentFundingGlaucomaIOLIndustryMicroscopesNewsletterRegulationRetina
April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

4/5/2024
BreakingCornealDeals
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts

West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...

3/29/2024
BreakingCornealDealsRetinaSurgical
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

3/29/2024
BreakingCataractCornealIndustryRefractiveSurgical
Alcon Appoints Terry Kim, MD, as CMO, Head of Global Medical Safety
Alcon Appoints Terry Kim, MD, as CMO, Head of Global Medical Safety

Alcon announced March 26 that Terry Kim, MD, would join the company in April as chief medical officer (CMO) and head of global medical safety. Kim, who specializes in cornea, cataract, and refracti...

3/22/2024
BreakingClinical TrialCornealRegulation
US FDA Gives Green Light to Phase I Trial of Fuchs’ Candidate from Design Therapeutics
US FDA Gives Green Light to Phase I Trial of Fuchs’ Candidate from Design Therapeutics

Design Therapeutics reported March 19 in its 2023 financial statement that the US FDA had cleared its investigational new drug (IND) application for a clinical trial of DT-168 in Fuchs’ endothelial...

3/21/2024
CornealGlaucomaNewsletterSurgical
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US

Israel-based CorNeat Vision announced Feb. 27 that it had launched its EverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first syn...

3/21/2024
CornealDealsDry EyeIOLIndustryNewsletterRegulationRetina
March 2024 Ophthalmic News Briefs
March 2024 Ophthalmic News Briefs

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

3/15/2024
BreakingCornealDry EyeIndustry
Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officer
Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officer

Vital Tears announced March 6 that it had appointed Joseph Tauber, MD, as its chief medical officer. In 2023, Vital Tears added mobile phlebotomy services to its system of providing autologous seru...

3/8/2024
BreakingCornealRegulationRetina
US FDA Approves Supplemental NDA for Pre-filled Acthar Gel Self-Injector
US FDA Approves Supplemental NDA for Pre-filled Acthar Gel Self-Injector

Ireland-based Mallinckrodt announced March 1 that the US FDA had approved its supplemental new drug application (sNDA) for the H.P. Acthar Gel single-dose pre-filled SelfJect injector. SelfJect pro...

3/1/2024
BreakingCornealDry EyeGlaucomaIOLRefractiveRetinaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus

Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...

3/1/2024
BreakingCornealGlaucomaSurgical
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US
CorNeat Vision Launches EverPatch Ophthalmic Graft Material in the US

Israel-based CorNeat Vision announced Feb. 27 that it had launched itsEverPatch scleral reinforcement patch in the US. The device was cleared by the US FDA in June 2023. The graft is the first synt...

2/23/2024
BreakingCornealFundingStudy
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea

Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...

2/23/2024
BreakingClinical TrialCornealDeals
Eversight Partners with Emmecell to Advance Corneal Cell Therapies
Eversight Partners with Emmecell to Advance Corneal Cell Therapies

Global nonprofit eye bank Eversight and Emmecell announced Feb. 20 that they would collaborate to advance cell therapies for corneal treatment. Emmecell, of Menlo Park, California, is developing EO...

2/22/2024
CornealFundingNewsletterStudy
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea

Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...

2/22/2024
CornealNewsletterStudy
Mass Eye and Ear Study Reveals that Neuropeptide Promotes Corneal Healing
Mass Eye and Ear Study Reveals that Neuropeptide Promotes Corneal Healing

A recent study by investigators at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology revealed that the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes cornea...

2/22/2024
CornealEmergingGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, February 2024
Emerging Companies Pursuing Ophthalmic Indications, February 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

2/16/2024
BreakingClinical TrialCornealRegulation
US FDA Gives Green Light to Phase II Trial of Okyo’s OK-101 in the First IND Cleared for Neuropathic Corneal Pain
US FDA Gives Green Light to Phase II Trial of Okyo’s OK-101 in the First IND Cleared for Neuropathic Corneal Pain

London’s Okyo Pharma announced Feb. 9 that the US FDA had cleared its investigational new drug (IND) application for topical candidate OK-101 in neuropathic corneal pain—a first for that indication...

2/9/2024
BreakingCornealIndustry
Stuart Therapeutics Names Jodi Luchs, MD, as Chief Medical Officer
Stuart Therapeutics Names Jodi Luchs, MD, as Chief Medical Officer

Stuart Therapeutics, of Stuart, Florida, reported Feb. 1 that it had appointed Jodi Luchs, MD, as chief medical officer. Luchs is a board-certified, fellowship-trained ophthalmologist with a subspe...

1/23/2024
CornealNewsletter
2023 in Review: Japan Approves Vyznova, World’s First Corneal Cell Therapy
2023 in Review: Japan Approves Vyznova, World’s First Corneal Cell Therapy

Cornea treatment made a significant breakthrough in 2023, with the approval in Japan of Aurion Biotech’s novel cell therapy, Vyznova, for the treatment of bullous keratopathy. The milestone is a gl...

1/23/2024
CornealDry EyeFundingNewsletterPresbyopiaRetina
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round

China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...

1/23/2024
CornealEmergingNewsletter
Emerging Companies Pursuing Ophthalmic Indications, January 2024
Emerging Companies Pursuing Ophthalmic Indications, January 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

1/23/2024
CataractCornealDealsDry EyeGene TherapyGlaucomaIndustryLaserNewsletterOCTRegulationRetina
January 2024 Ophthalmic News Briefs
January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

1/19/2024
BreakingCornealStudy
Mass Eye and Ear Study Shows Neuropeptide Promotes Corneal Healing
Mass Eye and Ear Study Shows Neuropeptide Promotes Corneal Healing

A recent study by investigators at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology revealed that that administration of the neuropeptide α-melanocyte-stimulating hormone ...

1/5/2024
BreakingCornealRegulation
US FDA Grants Orphan Drug Status to Cellusion’s Corneal Cell Therapy Candidate
US FDA Grants Orphan Drug Status to Cellusion’s Corneal Cell Therapy Candidate

Cellusion, of Tokyo, announced Dec. 22 that the US FDA had granted orphan drug designation to its induced pluripotent stem cell-derived corneal endothelial cell substitute, CLS001, for bullous kera...

12/29/2023
BreakingCornealFundingIndustry
KeraLink International Launches Cornea Accelerator, Issues $100K Challenge to Innovators
KeraLink International Launches Cornea Accelerator, Issues $100K Challenge to Innovators

KeraLink International, a nonprofit group focused on eradicating global corneal blindness, announced Dec. 11 that it had launched a Cornea Technology Accelerator, open to entrepreneurs and innovato...

11/21/2023
CornealDiagnosticDry EyeFundingGlaucomaNewsletterRetina
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A

EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...

11/21/2023
Clinical TrialCornealGlaucomaNewsletterRegulationRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, November 2023
Clinical Trial Updates for Ophthalmic Candidates, November 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

11/21/2023
CornealDiagnosticEmergingGene TherapyGlaucomaNewsletterRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, November 2023
Emerging Companies Pursuing Ophthalmic Indications, November 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/24/2023
CornealESCRSMeetingNewsletter
New Cornea Therapies Aim to Mitigate Unacceptable Outcomes
New Cornea Therapies Aim to Mitigate Unacceptable Outcomes

Cornea Subspecialty Day has become the most popular pre-meeting event at the annual congress of the European Society of Cataract and Refractive Surgeons, with 629 attendees this year. Cornea specia...

10/24/2023
CornealESCRSMeetingNewsletterSurgical
Ukrainian Ophthalmologists Endure Complex Surgical Cases Amid War
Ukrainian Ophthalmologists Endure Complex Surgical Cases Amid War

Ukrainian ophthalmologists are struggling to restore sight to soldiers and confronting complex surgical cases, even as the Russian offensive continues in their country. A large contingent of 825 Uk...

9/21/2023
CataractCornealDry EyeFundingGene TherapyNewsletterPharmaRetina
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue

Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...

9/21/2023
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, September 2023
Clinical Trial Updates for Ophthalmic Candidates, September 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

9/21/2023
ChinaClinical TrialCornealDealsDiagnosticDry EyeEuropeGene TherapyIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2023 Ophthalmic News Briefs
September 2023 Ophthalmic News Briefs

Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...

9/15/2023
BreakingCornealDeals
NovaBay will Commercialize BioStem Amniotic Tissue Ocular Allograft as Avenova Allograft
NovaBay will Commercialize BioStem Amniotic Tissue Ocular Allograft as Avenova Allograft

NovaBay Pharmaceuticals and BioStem Technologies announced an agreement Sept. 11 under which NovaBay will commercialize BioStem’s ocular amniotic tissue allograft. No financial details for the deal...

8/22/2023
CataractCornealDry EyeFundingGene TherapyIOLNewsletterPharmaRetinaSurgical
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....

8/22/2023
CornealEmergingMyopiaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2023
Emerging Companies Pursuing Ophthalmic Indications, August 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

8/22/2023
CornealNewsletterStudy
Cedars-Sinai Study Identifies How Diabetes Slows Healing in the Eye
Cedars-Sinai Study Identifies How Diabetes Slows Healing in the Eye

Investigators at Cedars-Sinai in Los Angeles say they’ve identified diabetes-associated epigenetic changes to the cornea, providing a new understanding of how the disease delays wound healing in th...

8/4/2023
BreakingCornealDealsEmerging
Verséa Ophthalmics Signs Deal to Distribute Celularity’s Amniotic Allografts in the US
Verséa Ophthalmics Signs Deal to Distribute Celularity’s Amniotic Allografts in the US

Celularity and Verséa Ophthalmics announced an exclusive US commercial agreement on July 27. Verséa will distribute Celularity’s Biovance and Biovance 3L for ocular surface disease and ocular surgi...

7/28/2023
BreakingCornealStudy
Cedars-Sinai Study Identifies How Diabetes Slows Healing in the Eye
Cedars-Sinai Study Identifies How Diabetes Slows Healing in the Eye

Investigators at Cedars-Sinai in Los Angeles say they’ve identified diabetes-associated epigenetic changes to the cornea, providing a new understanding of how the disease delays wound healing in th...

7/25/2023
CornealFundingGlaucomaNewsletterRetina
NeuroGene Leads Latest Ophthalmic Fundraising with $95 Million Private Placement
NeuroGene Leads Latest Ophthalmic Fundraising with $95 Million Private Placement

Neurogene led recent ophthalmic fundraising efforts with a $95 million private placement, as it advances its pipeline, including a gene therapy candidate for Batten disease. Funding announced in th...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more